SINTICA BIOTECH

Sintica Biotech is a biopharmaceutical company focused on the development of innovative treatments to address high unmet medical needs in dermato-oncological diseases... Sintica has focused its first-line activities on melanoma, a serious form of skin cancer that begins in cells known as melanocytes. Melanoma is the most invasive skin cancer with the highest risk of death. Sintica has developed a peptidomimetic, SNT001, addressing an unprecedented pharmacological target to induce apoptosis in melanoma cells... Sintica Biotech has been founded in November 2021 as a spin-off of the University of Modena and Reggio Emilia by Prof. Carlo Pincelli, Prof. Alessandra Marconi, and Dr. Silvio Traversa. Our mission is to provide new effective options to address unmet medical needs in melanoma.

VAT numbers: 12120000968

Primary location: Milano Italy